Compass Pathways Target of Unusually High Options Trading (NASDAQ:CMPS)

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) saw some unusual options trading activity on Wednesday. Investors purchased 10,217 put options on the company. This is an increase of approximately 70% compared to the typical volume of 6,015 put options.

Institutional Trading of Compass Pathways

Several institutional investors and hedge funds have recently modified their holdings of the business. Ancora Advisors LLC acquired a new position in Compass Pathways during the second quarter worth about $43,000. EverSource Wealth Advisors LLC boosted its stake in shares of Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock valued at $26,000 after purchasing an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of Compass Pathways during the 4th quarter valued at approximately $38,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Compass Pathways during the 4th quarter valued at approximately $47,000. Finally, Advisory Services Network LLC acquired a new position in Compass Pathways during the 3rd quarter worth approximately $41,000. 46.19% of the stock is currently owned by institutional investors.

Compass Pathways Price Performance

Shares of NASDAQ:CMPS traded down $0.09 during midday trading on Wednesday, hitting $14.79. The stock had a trading volume of 597,297 shares, compared to its average volume of 3,630,745. The company’s 50-day moving average price is $12.97 and its 200-day moving average price is $9.94. Compass Pathways has a fifty-two week low of $4.40 and a fifty-two week high of $15.40. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $2.05 billion, a P/E ratio of -3.20 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, equities research analysts predict that Compass Pathways will post -1.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CMPS shares. BTIG Research raised their price target on shares of Compass Pathways from $14.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Wells Fargo & Company started coverage on shares of Compass Pathways in a research report on Monday, July 27th. They set an “equal weight” rating and a $13.00 target price on the stock. Royal Bank Of Canada lowered their target price on shares of Compass Pathways from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Evercore upgraded shares of Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 price target for the company in a research report on Wednesday, July 8th. Finally, HC Wainwright cut their price target on Compass Pathways from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Compass Pathways presently has a consensus rating of “Moderate Buy” and an average target price of $23.36.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.